{"id":295323,"date":"2026-03-16T00:00:00","date_gmt":"2026-03-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algone0002-2023-biopharma-diabetic-nephropathy-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-03-31T10:23:17","modified_gmt":"2026-03-31T10:23:17","slug":"algone0002-2026-biopharma-diabetic-nephropathy-current-treatment-treatment-algorithms-claims-data-analysis-diabetic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algone0002-2026-biopharma-diabetic-nephropathy-current-treatment-treatment-algorithms-claims-data-analysis-diabetic\/","title":{"rendered":"Diabetic Nephropathy &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Diabetic Nephropathy (US)"},"content":{"rendered":"<p>Diabetic nephropathy (<abbr title=\"diabetic nephropathy\">DN<\/abbr>), also referred to as diabetic kidney disease, is a common complication of diabetes. The <abbr title=\"diabetic nephropathy\">DN<\/abbr> drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. The <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors are increasingly recognized as transformative agents in the <abbr data-abbreviation-entity=\"6300\" title=\"diabetic nephropathy\">DN<\/abbr> market, with growing clinical adoption. The use of Bayer\u2019s finerenone (Kerendia), the first and only <abbr data-abbreviation-entity=\"7152\" title=\"mineralocorticoid receptor antagonist\">MRA<\/abbr> approved by the <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> for <abbr data-abbreviation-entity=\"6300\" title=\"diabetic nephropathy\">DN<\/abbr>, is expanding gradually. In addition, the role of <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products, such as <abbr data-abbreviation-entity=\"4958\" title=\"subcutaneous\">SC<\/abbr> semaglutide (Ozempic), is also growing progressively for <abbr data-abbreviation-entity=\"6300\" title=\"diabetic nephropathy\">DN<\/abbr>. This report provides important insights into how these agents are used in the management of diabetic nephropathy and into evolving practices.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"diabetic nephropathy\">DN<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"diabetic nephropathy\">DN<\/abbr> patients?<\/li>\n<li>How have <abbr data-abbreviation-entity=\"5590\" title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors been integrated into the treatment algorithm, and what is their sources of business?<\/li>\n<li>What percentage of <abbr title=\"diabetic nephropathy\">DN<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"diabetic nephropathy\">DN<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> Boehringer Ingelheim<b>, <\/b>AstraZeneca, Bayer, Johnson &#038; Johnson innovative medicine, Amgen, Novo Nordisk, Eli Lilly<\/p>\n<p><strong>Key drugs:<\/strong> <abbr data-abbreviation-entity=\"5703\" title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors, beta blockers, <abbr data-abbreviation-entity=\"5686\" title=\"calcium channel blocker\">CCB<\/abbr>s, <abbr data-abbreviation-entity=\"7152\" title=\"mineralocorticoid receptor antagonist\">MRA<\/abbr>s, insulins, <abbr data-abbreviation-entity=\"5029\" title=\"dipeptidyl peptidase\">DPP<\/abbr>-4 inhibitors, <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors, <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products<\/p>\n<p><strong>Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-295323","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-pain","biopharma-therapy-areas-diabetic-nephropathy","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":7,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295323\/revisions"}],"predecessor-version":[{"id":575178,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295323\/revisions\/575178"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}